Automated planning of curved needle channels in 3D printed patient-tailored applicators for cervical cancer brachytherapy.
Robin Straathof, Sharline M van Vliet-Pérez, Inger-Karine K Kolkman-Deurloo...
https://pubmed.ncbi.nlm.nih.gov/39447602/Actively Recruiting
Led by Erasmus Medical Center · Updated on 2026-09-25
25
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the clinical feasibility of the patient-tailored ARCHITECT applicator in brachytherapy for locally advanced cervical cancer LACC. This phase I, prospective, non-randomised, single-centre trial aims to address limitations in current applicators used during brachytherapy, which may not meet dose objectives in certain patients. The study involves 25 patients receiving standard LACC treatment following EMBRACE II protocol and national guidelines. Participants will undergo external beam radiation therapy 45 Gy in 25 fractions with possible nodal boost, concurrent weekly chemotherapy with cisplatin, and high-dose rate HDR image-guided adaptive brachytherapy IGABT. Brachytherapy involves two applications one week apart the first uses a standard commercial applicator, and the second uses the patient-specific 3D-printed ARCHITECT applicator. Deep hyperthermia during EBRT is allowed but not required. During the study, participants will be monitored for clinical feasibility at week 2 with the ARCHITECT applicator, as well as for brachytherapy-related adverse events, plan quality, implant geometry, user experience, workflow time, pain levels, and applicator integrity at both week 1 and week 2. Assessments include imaging, pain questionnaires, and safety evaluations before, during, and shortly after applicator removal. The study is expected to complete by December 2027.
CONDITIONS
Clinical Feasibility of the ARCHITECT Applicator in Cervical Cancer Brachytherapy
H
H. Westerveld, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Erasmus Medical Center
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 2 weeks
Participants undergo two brachytherapy applications one week apart. The first application uses a standard commercial applicator, and the second uses the patient-tailored ARCHITECT applicator. External beam radiation therapy and chemotherapy are also given according to standard protocols.
2 visits, one per brachytherapy application
Duration - Up to 2 weeks after treatment
Participants are monitored for brachytherapy-related adverse events, treatment plan quality, implant geometry, user experience, workflow time, pain levels, and device integrity after each brachytherapy session.
Multiple assessments after each application
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Robin Straathof, Sharline M van Vliet-Pérez, Inger-Karine K Kolkman-Deurloo...
https://pubmed.ncbi.nlm.nih.gov/39447602/Erasmus Medical Center
Lead Sponsor